Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients

Figure 1 Correlation between the serum concentration. Correlation between the serum concentration of interleukin 17 (IL-17) and IL-23 in Crohn’s disease patients (r = 0.48182, P = 0.007).

Figure 2 Interleukin 17A, interleukin 23 and interferon gamma serum concentration in controls and Crohn’s disease patients with and without skin adverse side effects of anti-tumor necrosis factor-α therapy. Interleukin 17A (IL-17A): With skin lesions vs without skin lesions: P = 0.000044; with skin lesions vs control: P = 0.000005; without skin lesions vs control: P = 0.000037; IL-23: With skin lesions vs without skin lesions: P = 0.005557; with skin lesions vs control: P = 0.000005; without skin lesions vs control: P = 0.000037; interferon gamma (IFN-γ): With skin lesions vs without skin lesions: P = 0.966233; with skin lesions vs control: P = 0.000005; without skin lesions vs control: P = 0.000037.

Figure 3 Scatter plot. Scatter plot showing correlation between hemoglobin rate and interleukin 17A (IL-17A) serum levels in Crohn’s disease patients (r = 0.505, P = 0.01).